Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | abstract | ||||||||||||
PMID | |||||||||||||
Authors | Y. Honma, I. Kinoshita, C. Ishioka, K. Ishigaki, T. Enokida, H. Hayashi, S. Nishiwaki, N. Nishida, M. Muto, M. Tabata, M. Ito, R. Ko, K. Sunami, T. Shimoi, N. Yamamoto | ||||||||||||
Title | 621P Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901) | ||||||||||||
|
|||||||||||||
URL | https://www.annalsofoncology.org/article/S0923-7534(24)02207-5/fulltext | ||||||||||||
Abstract Text | Background BRAF gene alterations, representing BRAF V600E mutation, are prevalent in melanoma, thyroid cancer, non-small cell lung cancer, and other malignancies to a lesser degree. The BELIEVE trial is a single-arm, open-label Japanese multi-institutional study equivalent to the NCI-MATCH trial, and we report the results of the cohort that assessed the efficacy of E+B in BRAF-altered solid tumors refractory to standard of care. Methods Pts with solid tumors recommended E+B in molecular tumor board based on comprehensive genomic profiling were eligible. Participants received Encorafenib 450 mg once daily and Binimetinib 45 mg twice daily continuously until disease progression or intolerable toxicity occurred. The primary endpoint was the investigator-assessed objective response rate (ORR) according to the RECIST v1.1. The clinical hypothesis was that patients would respond to the genotype-matched drugs. Bayesian analysis using a prior distribution with an expected ORR of 30% [Beta (0.6, 1.4)] was carried out. Results Forty-nine pts were extracted as a full analysis set with a median age of 65. The primary site of 23 pts was thyroid, central nervous system in 6, and biliary tract in 4. BRAF V600E mutation was detected in 43 pts, other BRAF mutation in 5, and BRAF fusion in 1, respectively. The confirmed ORR was 32.7% (95% CI, 20.0-47.5), which showed expected efficacy. Median PFS and PFS rate at 6 months were 4.8 months (95% CI, 2.2-6.9) and 37.5%. Data regarding overall survival was premature, with a median of 11.7 months at the time of analysis. Furthermore, the median PFS was 2.1 months (95% CI, 0.6 to 10.9 months) for the eight patients without target lesions in the exploratory analysis. Frequently observed adverse events (AEs) in a safety analysis set (58 pts) were ALT increased (8.6%), nausea (6.9%), anemia (6.9%), creatinine increased (6.9%), and CPK increased (6.9%). Grade ≥3 AEs was observed in 34.5%. Conclusions This study showed the efficacy of matched drubs with an ORR of 32.7%, and other clinical outcomes also encouraged the efficacy of E+B in BRAF-altered solid tumors. |